Abstract
Technical aspects including technology for plasma-exchange, anticoagulation, blood access and blood substitutes are reviewed. The consequences of exchange on the level of various proteins are analyzed considering especially their role in coagulation disorders and immunomodulation. The complications which have been published and those which have been the result of a French inquiry are extensively analyzed. The mortality in this later experience is around 1% represented by non-cardiac pulmonary edema and cardiac circulatory failure. The factors which can reduce hazards are reviewed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
